Letrozole vs Tamoxifen
FDA Approved vs FDA Approved
monitor Researched · 90% Unlike anastrozole, letrozole does not appear to significantly reduce endoxifen concentrations. However, combining a SERM with an aromatase inhibitor can lead to excessive estrogen suppression. Use with caution and monitor estradiol levels and symptoms.
Molecular Data
Letrozole Tamoxifen
Weight 285.30 Da 371.51 Da
Half-life ~2 days (48 hours) ~5-7 days
Type Nonsteroidal aromatase inhibitor (triazole derivative) Triphenylethylene-derived selective estrogen receptor modulator
Key Benefits
Letrozole
01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Side Effects
Letrozole
Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
Fatigue and profound lethargy
Mood disturbance (depression, emotional flatness, irritability)
Decreased libido and sexual dysfunction
Hot flashes or flushing
Headache
Muscle aches and generalized pain
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Contraindications
Known hypersensitivity to letrozole or any excipients
Premenopausal women (unless under specialist care for fertility treatment)
Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
History of estrogen-crash-related adverse events with prior AI use
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Research Evidence
Letrozole Tamoxifen
Status FDA Approved FDA Approved
References 5 studies 5 studies
FDA Approved Yes Yes
More comparisons: HCG
This comparison is for educational and research purposes only. Consult a healthcare professional before use.